Wall Street brokerages predict that Cue Biopharma Inc (NASDAQ:CUE) will post earnings per share (EPS) of ($0.44) for the current quarter, according to Zacks. Zero analysts have provided estimates for Cue Biopharma’s earnings. Cue Biopharma reported earnings of ($0.62) per share in the same quarter last year, which would indicate a positive year over year growth rate of 29%. The company is scheduled to announce its next quarterly earnings results on Tuesday, November 12th.
On average, analysts expect that Cue Biopharma will report full-year earnings of ($1.96) per share for the current financial year. For the next year, analysts expect that the business will post earnings of ($1.35) per share. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Cue Biopharma.
Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.10. The firm had revenue of $1.06 million during the quarter. Cue Biopharma had a negative return on equity of 151.93% and a negative net margin of 2,039.41%.
Cue Biopharma stock traded up $0.19 during trading hours on Friday, hitting $7.72. The stock had a trading volume of 54,454 shares, compared to its average volume of 87,090. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.65 and a quick ratio of 2.65. The stock has a market capitalization of $174.34 million, a price-to-earnings ratio of -3.98 and a beta of 1.20. Cue Biopharma has a 1-year low of $4.16 and a 1-year high of $9.94. The stock’s fifty day moving average is $8.28 and its two-hundred day moving average is $8.14.
Institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in shares of Cue Biopharma by 21.3% during the second quarter. BlackRock Inc. now owns 1,148,126 shares of the company’s stock valued at $10,321,000 after acquiring an additional 201,986 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Cue Biopharma by 33.8% during the second quarter. Vanguard Group Inc. now owns 612,151 shares of the company’s stock valued at $5,504,000 after acquiring an additional 154,639 shares during the last quarter. Rock Creek Group LP acquired a new stake in shares of Cue Biopharma during the second quarter valued at $447,000. Strs Ohio boosted its stake in shares of Cue Biopharma by 500.0% during the second quarter. Strs Ohio now owns 15,000 shares of the company’s stock valued at $134,000 after acquiring an additional 12,500 shares during the last quarter. Finally, Sigma Planning Corp boosted its stake in shares of Cue Biopharma by 13.6% during the second quarter. Sigma Planning Corp now owns 47,805 shares of the company’s stock valued at $430,000 after acquiring an additional 5,706 shares during the last quarter. 19.93% of the stock is currently owned by institutional investors.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Featured Article: How is Preferred Stock Different from Common Stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.